Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25433772 | 1.00 | RAD51 (0.56) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25430584 | 1.00 | RAD51 (0.56) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25432110 | 0.91 | MEN1 (0.58) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL26064225 | 0.91 | MEN1 (0.58) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL26064226 | 0.91 | MEN1 (0.58) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25433024 | 0.90 | MEN1 (0.50) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25432966 | 0.90 | RAD51 (0.58) | RAD51KMT2AMEN1 | |
| SCHEMBL25434505 | 0.90 | MEN1 (0.49) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25432658 | 0.90 | RAD51 (0.55) | RAD51KMT2AMEN1KDM4EALDH1A1 | |
| SCHEMBL25431800 | 0.90 | MEN1 (0.49) | RAD51KMT2AMEN1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | claimed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | RAD51 1/4885KMT2A 2879/4885MEN1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.